Research Reagents

anti-C-Myc Antibody (Chicken) - FITC Conjugated

Catalog #
CMYC-45F-Z
Product Size
0.1 mg
$210.00
More Information
Antibody Type Primary Antibody
Reactivity C-Myc Tag
Host Chicken
Specificity/Target C-Myc tag
Size 0.1
Clonality Polyclonal
Type FITC Conjugated
Isotype IgY
Origin USA
Shelf Life 1 year
Format Liquid
Buffer Phospate buffered saline, pH 7.2 with 0.2% BSA
Preservative 0.09% sodium azide
Storage 2-8C
Application ELISA
Purity Antigen Affinity Purified
Data Sheet
PP_CMYC-45F-Z.pdf
SDS
ICL_SDS_CMYC-45F_and_Z_1.pdf

Moulana A, Dupic T, Phillips AM, et al. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. Elife. 2023;12:e83442. Published 2023 Feb 21. doi:10.7554/eLife.83442

Willis JR, Berndsen ZT, Ma KM, et al. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity. 2022;55(11):2149-2167.e9. doi:10.1016/j.immuni.2022.09.001

Cao Y, Jian F, Zhang Z, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022;41(12):111845. doi:10.1016/j.celrep.2022.111845

Zhao F, Keating C, Ozorowski G, et al. Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. iScience. 2022;25(9):104914. doi:10.1016/j.isci.2022.104914

Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4):100255. doi:10.1016/j.xcrm.2021.100255

Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463-476.e6. doi:10.1016/j.chom.2021.02.003

McShan, A.C., Devlin, C.A., Morozov, G.I. et al. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap. Nat Commun 12, 3174 (2021). https://doi.org/10.1038/s41467-021-23225-6

Greaney AJ. et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition, Cell Host & Microbe,Volume 29, Issue 1,2021,Pages 44-57.e9,ISSN 1931-3128, https://doi.org/10.1016/j.chom.2020.11.007.

Starr TN, Greaney AJ, Hilton SK. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182(5):1295-1310.e20. doi:10.1016/j.cell.2020.08.012

Day A et al. Unintended specificity of an engineered ligand-binding protein facilitated by unpredicted plasticity of the protein fold Protein Engineering, Design & Selection, 2018, pp. 1–13 doi: 10.1093/protein/gzy031

Dou J. et al. Sampling and energy evaluation challengesin ligand binding protein design. Protein Science 2017 VOL 26:2426—2437. DOI: 10.1002/pro.3317

Steichen et al. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity (2016), http://dx.doi.org/10.1016/j.immuni.2016.08.016

Kalkan T. et al. Tumor Necrosis Factor-Receptor–associated Factor-4 Is a Positive Regulator of Transforming Growth Factor-β Signaling That Affects Neural Crest Formation Mol. Biol. Cell July 15, 2009 vol. 20 no. 14 3436-3450

Wright J. et al. Dominant protein interactions that influence the pathogenesis of conformational diseases J Clin Invest. 2013;123(7):3124-3134. doi:10.1172/JCI67260.

Baxter S. et al. Flow Cytometric Assays for Interrogating LAGLIDADG Homing Endonuclease DNA-Binding and Cleavage Properties Methods Mol Biol. 2013; 978: 45–61.doi: 10.1007/978-1-62703-293-3_4

Procko E. et al. Computational design of a protein-based enzyme inhibitor J Mol Biol. 2013 Sep 23; 425(18): 10.1016/j.jmb.2013.06.035.

View product citations for antibodies CMYC-45F-Z on CiteAb
Publishing research using our antibodies or ELISA kits? TELL US AND RECEIVE A $150 COUPON
All Content ICL, Inc. All Rights Reserved